000147346 001__ 147346
000147346 005__ 20240229112648.0
000147346 0247_ $$2doi$$a10.3390/biom9100605
000147346 0247_ $$2pmid$$apmid:31614935
000147346 0247_ $$2altmetric$$aaltmetric:68297929
000147346 037__ $$aDKFZ-2019-02467
000147346 041__ $$aeng
000147346 082__ $$a570
000147346 1001_ $$0P:(DE-He78)43b43c5f20ed70299251a446ad8ec973$$aSrivastava, Aayushi$$b0$$eFirst author$$udkfz
000147346 245__ $$aWhole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways.
000147346 260__ $$aBasel$$bMDPI$$c2019
000147346 3367_ $$2DRIVER$$aarticle
000147346 3367_ $$2DataCite$$aOutput Types/Journal article
000147346 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634561177_21236
000147346 3367_ $$2BibTeX$$aARTICLE
000147346 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147346 3367_ $$00$$2EndNote$$aJournal Article
000147346 500__ $$a2019, 9(10), 605
000147346 520__ $$aEvidence of familial inheritance in non-medullary thyroid cancer (NMTC) has accumulated over the last few decades. However, known variants account for a very small percentage of the genetic burden. Here, we focused on the identification of common pathways and networks enriched in NMTC families to better understand its pathogenesis with the final aim of identifying one novel high/moderate-penetrance germline predisposition variant segregating with the disease in each studied family. We performed whole genome sequencing on 23 affected and 3 unaffected family members from five NMTC-prone families and prioritized the identified variants using our Familial Cancer Variant Prioritization Pipeline (FCVPPv2). In total, 31 coding variants and 39 variants located in upstream, downstream, 5' or 3' untranslated regions passed FCVPPv2 filtering. Altogether, 210 genes affected by variants that passed the first three steps of the FCVPPv2 were analyzed using Ingenuity Pathway Analysis software. These genes were enriched in tumorigenic signaling pathways mediated by receptor tyrosine kinases and G-protein coupled receptors, implicating a central role of PI3K/AKT and MAPK/ERK signaling in familial NMTC. Our approach can facilitate the identification and functional validation of causal variants in each family as well as the screening and genetic counseling of other individuals at risk of developing NMTC.
000147346 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147346 588__ $$aDataset connected to CrossRef, PubMed,
000147346 7001_ $$0P:(DE-He78)da09d83faa85c143d15611698f7b1eac$$aKumar, Abhishek$$b1
000147346 7001_ $$0P:(DE-He78)f18e077aae13edd9d0d8b911cfcd8e0f$$aGiangiobbe, Sara$$b2
000147346 7001_ $$aBonora, Elena$$b3
000147346 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$udkfz
000147346 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b5$$udkfz
000147346 7001_ $$0P:(DE-He78)b11ccde1801d45d32a6a60f7b396d7dc$$aBandapalli, Obul Reddy$$b6$$eLast author$$udkfz
000147346 773__ $$0PERI:(DE-600)2701262-1$$a10.3390/biom9100605$$gVol. 9, no. 10, p. 605 -$$n10$$p605$$tBiomolecules$$v9$$x2218-273X$$y2019
000147346 909CO $$ooai:inrepo02.dkfz.de:147346$$pVDB
000147346 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43b43c5f20ed70299251a446ad8ec973$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000147346 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)da09d83faa85c143d15611698f7b1eac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000147346 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f18e077aae13edd9d0d8b911cfcd8e0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147346 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000147346 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000147346 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b11ccde1801d45d32a6a60f7b396d7dc$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000147346 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147346 9141_ $$y2019
000147346 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147346 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147346 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147346 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000147346 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000147346 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000147346 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000147346 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000147346 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000147346 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000147346 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147346 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147346 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147346 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147346 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000147346 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000147346 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000147346 980__ $$ajournal
000147346 980__ $$aVDB
000147346 980__ $$aI:(DE-He78)C050-20160331
000147346 980__ $$aI:(DE-He78)B062-20160331
000147346 980__ $$aI:(DE-He78)L101-20160331
000147346 980__ $$aUNRESTRICTED